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a b s t r a c t
Radiation proctitis, an inﬂammation and damage to the lower part of colon, is a common adverse event
of the radiotherapy of tumors in the abdominal and pelvic region (colon, prostate, cervical). Several
Mn(III) porphyrin-based superoxide dismutase mimics have been synthesized and successfully evaluated
in preclinical models as radioprotectants. Here we report for the ﬁrst time the remarkable rectal radio-
protection of frequently explored Mn(III) meso-tetrakis(N-ethylpyridinium-2-yl)porphyrin, MnTE-2-
PyP5þ . A batch prepared in compliance with good manufacturing practice (GMP), which has good
safety/toxicity proﬁle, was used for this study. MnTE-2-PyP5þ was given subcutaneously at 5 mg/kg,
either 1 h before or 1 h after irradiation, with additional drug administered at weekly intervals thereafter.
MnTE-2-PyP5þ ameliorated both acute and chronic radiation proctitis in male Sprague-Dawley rats
irradiated with 20–30 Gy protons delivered to 2.5 cm span of rectum using spread-out Bragg peak of a
proton treatment beam. Focal irradiation of the rectum produced acute proctitis, which healed, followed
by chronic rectal dilation and symptomatic proctitis. MnTE-2-PyP5þ protected rectal mucosa from
radiation-induced crypt loss measured 10 days post-irradiation. Signiﬁcant effects were observed with
both pre- and post-treatment regimens. However, only MnTE-2-PyP5þ pre-treatment, but not post-
treatment, prevented the development of rectal dilation, indicating that proper dosing regimen is critical
for radioprotection. The pre-treatment also prevented or delayed the development of chronic proctitis
depending on the radiation dose. Further work aimed at developing MnTE-2-PyP5þ and similar drugs as
adjunctive agents for radiotherapy of pelvic tumors is warranted. The present study substantiates the
prospects of employing this and similar analogs in preserving normal tissue during cancer radiation as
well as any other radiation exposure.
& 2013 The Authors. Published by Elsevier B.V.
Introduction
Radiation is a cost-effective treatment, and plays central role in
cancer treatment and is a major cure for 25% of all cancers [1].
Yearly, over 200,000 patients receive abdominal or pelvic radiation
therapy, and the estimated number of cancer survivors with post-
radiation intestinal dysfunction is 1.5–2 million [2]. The risk of
injury to the intestine is dose limiting during the radiation therapy
of abdominal and pelvic region such as in the treatments of colon,
cervical and prostate cancers. Delayed bowel toxicity is difﬁcult
to manage and adversely impacts the quality of life of cancer
survivors. Worthwhile progress towards reducing toxicity of
radiation therapy has been made by dose-sculpting treatment
techniques. The radiation damage to the gastrointestinal (GI) tract
is a concern in both clinical practice and in the context of
accidental radiological exposures and nuclear terrorist attacks
[1,3–6]. Recent study showed that 47% of women who received
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radiotherapy for cervical or endometrial cancer reported symp-
toms of radiation-related intestinal injury within 3 months follow-
ing therapy completion, which affected their quality of life [5].
These results are consistent with data from a survey showing that
53% of patients had reported that bowel symptoms signiﬁcantly
affect their quality of life, whilst 81% of patients described new-
onset gastrointestinal problems after receiving radiotherapy [1,5].
Radiation proctitis, inﬂammation and damage to the lower
parts of the colon, is a common adverse event associated with
radiotherapy of tumors in the pelvic region; for review see Ref. [7].
It can arise as either an acute or late response to treatment (or
both) [1,3–6]. The recent data on dose–volume effect in radiation
induced rectal injury was reviewed by Michalski et al. [8] and by
Shadad et al. [1,5]. Brieﬂy, the acute symptoms, like nausea,
vomiting, abdominal pain and diarrhea usually settle within three
weeks after completion of radiotherapy [1]. Delayed effects usually
follow progressive course starting at several months and up to
several years after radiation. Those effects are: bowel toxicity,
intermittent diarrhea, constipation due to altered colon motility
(as a consequence of ﬁbrosis and stricture formation), recurrent
pain, and increased risk of obstruction or pseudo-obstruction
secondary to fecal loading [1]. Excessive ﬁbrosis can cause loss of
ano-rectal compliance and manifests as urgency and frequency.
Fecal incontinence has been reported in up to 20% of patients and
signiﬁcantly reduces patients' quality of life.
Different pathological processes contribute to the development
of the acute and late responses and both are triggered by pro-
inﬂammatory mediators released in response to reactive species
formed in the GI epithelium during irradiation. Acute effects are also
the result of mitotic inhibition or loss of crypt cells that populate the
mucosal lining and result in disruption of the epithelial mucosa.
Signiﬁcant loss of epithelial mucosa, for example in accidental radia-
tion exposure or nuclear terrorist attack inwhich a large fraction of the
GI tract may be irradiated, can result in a life-threatening condition
due to the loss of GI barrier and transport functions.
Animal models have been developed that mimic the adverse
effects of GI irradiation observed clinically [9–14]. The general
pattern observed in these studies include (i) an acute phase
characterized by the loss of surface epithelial cells, crypt cells,
and crypts, and (ii) a late phase that evolved during the subse-
quent 4–6 months following irradiation. The late phase at the
higher dose range would eventuate in animal death from intestinal
obstruction [15–17]. Around 20% of the animals in the Trott model
of chronic proctitis died from hydronephrosis rather than
radiation-induced GI complications due to unintended irradiation
of the bladder/ureter [10,17]. The hydronephrosis, literally water in
kidney, refers to the distension and dilation of the renal pelvis and
calyces, usually caused by obstruction of the free ﬂow of urine
from the kidney. The radiosensitivity of the ureter was studied by
Knowles and Trott, who showed that doses as low as 10 Gy
delivered to the rat ureter (below the dose range used to produce
chronic proctitis in rats) could produce hydronephrosis [18].
Proton beam therapy vs. X-ray treatment
One of the goals of the present study was to improve on earlier
methods for irradiating the rat rectum by reducing the dose
delivered to other organs using proton beams rather than X-rays.
High energy proton beams stop abruptly in tissue at the end of
their range, deposit most energy in tissues of interest and thus
distribute dose in superior manner relative to X-rays [1]. Proton
therapy (PT) is more densely ionizing along the treatment path
allowing higher quantum energy and high linear energy transfer
to kill cancer (see also Material and methods Section). It is a very
promising modality for larger tumors which could be radiated at
high doses without signiﬁcant exposure of surrounding normal
tissue. With hepatocellular carcinoma proton beam therapy was
effective, safe and well tolerated in clinical studies. The relative
biological effectiveness (RBE) in clinical practice for protons is 1.1;
in turn the linear energy transfer (LET) is not much different over
most of the treatment path in comparison to photon radiation. In
clinical practice the PT is not considered a high LET treatment
modality, e.g., like other higher mass particle beam therapy (e.g.,
carbon). The dose distribution still remains a major difference
between the proton and conventional X-ray therapy. Although
new X-ray technologies are pretty much identical to PT in
Fig. 1. Therapeutic effects of Mn porphyrins. Ar indicates meso (the bridge in between two pyrrolic rings) aromatic either ortho N-alkylpyridyl groups [alkyl being ethyl in
MnTE-2-PyP5þ or n-hexyl in MnTnHex-2-PyP5þ], or ortho N-alkoxyalkylpyridyl substituents [alkoxyalkyl being n-butoxyethyl in MnTnBuOE-2-PyP5þ], or di-ortho N,N’-
dialkylimidazolyl substituents [alkyl being ethyl in MnTDE-2-ImP5þ]. Ortho position is the position on pyridyl or imidazolyl rings closest to the meso position. SCI¼spinal
cord injury, SH¼subarachnoid hemorrhage, CP¼cerebral palsy, ALS¼amyotrophic lateral sclerosis, PD¼Parkinson's disease, AD¼Alzheimer's disease, HSC¼hematopoietic
stem cells, GI¼gastrointestinal tract. See for details on therapeutic effects in Refs. [21,44,45].
J.O. Archambeau et al. / Redox Biology 1 (2013) 599–607600
conﬁning the dose in the vicinity of the target, PT offers reduced
“integral dose” to normal tissue.
Mn(III) meso-tetrakis(N-ethylpyridinium-2-yl)porphyrin (MnTE-
2-PyP5þ , AEOL10113, BMX-010) is a potent SOD mimic, peroxyni-
trite scavenger as well as scavenger of a number of other species
[19–22]. The meso (the bridges between two pyrrolic units) posi-
tions (indicated as Ar, aromatic rings) in MnTE-2-PyP5þ are
occupied with N-ethylpyridyl groups (Fig. 1). MnTE-2-PyP5þ was
developed based on structure–activity relationship between the
redox ability of metalloporphyrins described with metal-centered
reduction potential, E1/2 and their ability to dismute superoxide
described by the rate constant for the catalysis of O2 dismutation,
kcat(O2) [21,23,24]. The log kcat(O2) is 7.76 for MnTE-2-PyP5þ
while 8.84–9.2 for SOD enzymes (see review [21] for details). The
cationic charges in close vicinity of the metal site (ortho position)
are critical for its SOD-like activity as they afford the thermody-
namic and electrostatic facilitation for the approach of negatively
charged superoxide, peroxynitrite and a number of other anionic
species thought to be involved in the action of this compound, such
as hypochlorite, monodeprotonated ascorbate, monodeprotonated
hydrogen peroxide and thiolates [21]. The positive charges allow this
and similar cationic compounds to accumulate in mitochondria and
tissues rich in phospholipids, i.e. anionic phosphate groups [21].
MnTE-2-PyP5þ is among the most potent SOD mimics and perox-
ynitrite scavengers thus far reported and the most studied Mn
porphyrin-based SOD mimic (see contributions to Forum Issue on
“SOD therapeutics” in Antioxid Redox Signaling, also [21]). It has
shown remarkable potency in numerous animal models of oxidative
stress injuries [19]. The compound is also reactive towards simple
thiols (GSH, L-cysteine, N-acetylcysteine) [21,25,26] and protein
thiols which seems to be at least in part involved in its in vivo
mechanism/s of action/s. It has been recently substantiated that in
the presence of elevated H2O2 levels, the MnTE-2-PyP5þ would
oxidize or S-glutathionylate (along with GSH) p65 and p50 subunits
of master transcription pro-survival factor, NF-κB which would in
turn suppress inﬂammatory pathways [27]. Such reactivites may be
operative wherever excessive and cycling inﬂammation is involved
[21]. Needless to say such thiol modiﬁcations by MnPs have pro-
oxidative character, yet result in antioxidative effects – suppression of
NF-κB activation, i.e. inﬂammation (see [21] for details on type of
actions and related circumstances). In addition, the impact of MnTE-
2-PyP5þ on AP-1, HIF-1α and SP-1 have been demonstrated
[19–22,28]. Therefore, we recently prefer to regard this and similar
compounds rather as redox-regulators of cellular transcriptional
activities than as SOD mimics. Importantly, though, the magnitude
of their SOD-like activity, described by kcat(O2) parallels the
magnitude of their therapeutic efﬁcacy. Thus targeting SOD-like
activity is still a valuable approach for developing potent redox-
active drugs. MnTE-2-PyP5þ and related Mn porphyrin-based SOD
mimics [such as Mn(III) meso-tetrakis(N,N’-diethylimidazolium-2-yl)
porphyrin, MnTDE-2-ImP5þ (AEOL10150); Mn(III) meso tetrakis(N-
methylpyridinium-2-yl)porphyrin, MnTM-2-PyP5þ (AEOL10112);
and Mn(III) meso tetrakis(N-n-hexylpyridinium-2-yl)porphyrin,
MnTnHex-2-PyP5þ] have been reported to protect normal lung
[29,30], prostate [31–33], whole body [34,35], eye [28,36], salivary
glands and brain tissue from radiation damage [21,29,37–41]. The
accumulation of cationic Mn porphyrins, including MnTE-2-PyP5þ
and MnTnHex-2-PyP5þ in mitochondria [21,42,43] contributes to
their exceptional therapeutic efﬁcacy in a variety of diseases indicated
in Fig. 1, which all bear some components of the perturbance in
physiological redox environment. The therapeutic effects of Mn
porphyrins in different models of animal diseases are reviewed in
details in Forum Issue on “SOD therapeutics” in Antioxidants and Redox
Signaling [19,21,22,44,45].
A MnTE-2-PyP5þ batch, compliant with Good Manufacturing
Practice, was synthesized and the data on its excellent safety/
toxicity proﬁle have been reported [9]. Whenever brain is not a
key therapeutic target (as MnTE-2-PyP5þ has low ability to cross
blood brain barrier), MnTE-2-PyP5þ may be a superior candidate
for clinical development. The main objective of the present study
was to determine whether systemic administration of MnTE-2-
PyP5þ would ameliorate radiation damage to the rectum and the
development of acute and/or chronic radiation proctitis. This work
is the ﬁrst report on MnTE-2-PyP5þ radioprotection of GI tract
where injuries occur when abdominal and pelvic regions are
radiated.
Material and methods
All animal studies were reviewed and approved by the Loma
Linda University Animal Care and Use Committee. A GMP batch
of MnTE-2-PyP5þ was provided by National Jewish Health for
this study.
Irradiation of the rectum
All irradiations were performed using male Sprague-Dawley
rats weighing approximately 300 g. Animals were anesthetized
with isoﬂurane for the duration of the irradiation procedure. After
anesthesia induction, animals were secured to a ﬁxation platform
and then mounted on a positioning device with the 1.52.5 cm
treatment beam entering the posterior (dorsal) surface. The
position of the animal was then aligned using a light beam
projected through the beam collimator and helium–neon align-
ment lasers. The long axis of the treatment beam was oriented in
the rostral–caudal direction centered on midline with the caudal
edge of the beam located 2.5 cm from the anus. In preliminary
studies, ﬁeld locations were identiﬁed using barium-contrasted CT
and gadolinium-contrasted MRI, and conﬁrmed with radiographs.
A modulated, range-shifted proton beam was used to deliver the
prescribed dose. Range shifting was used to position the shoulder
of the treatment beam dose fall-off beyond the wall of the rectum,
2.5 cm into the body. 6 rats per group were studied. This setup was
selected to ensure that all the animals received the prescribed
dose over the full circumference of the rectum while minimizing
the dose delivered to distal organs (bladder and ureter). A semi-
conductor dosimeter inserted into the rectum was used to conﬁrm
the dose delivered to the target. In all studies reported, a
modulated proton beam was used to deliver the required dose to a
1.5 cm wide2.5 cm long2.5 cm deep rectal volume, 2.5 cm
proximal to the anus. The 20–35 Gy protons were delivered to
2.5 cm span of rectum in male Sprague-Dawley rats using spread-
out Bragg peak of a proton treatment beam. The relative biological
effectiveness of the proton beamwas taken to be 1.1, and all doses are
reported as cobalt gray equivalents (CGE) [46]. Following the thinking
of Van den Aardweg that the use of purgatives and metal insertions
to localize the ﬁeld altered the epithelial cell kinetics, it was decided
not to utilize a purgative enema prior to irradiation [47].
The technique of “spreading out” the proton treatment beam is
used both clinically and in the present study to ensure that a
uniform dose is delivered over a range of depths, and to treat any
target with axial dimension greater than few mm. The distal edge
of the spread-out Bragg peak falls from 90% to 10% in few mm. To
generate a uniform dose over a target at a greater range of depths
than the Bragg Peak width the beam energy and intensity are
moderated to generate successively shallower end of range beams.
The full width at half maximum of the Bragg Peak for 200 MeV
protons is about 2 cm; the maximum depth in tissue is about
25 cm. Single doses of protons for clinical cancer therapy range
from 10 to 30 Gy, fractionated treatments from 10 to 15 Gy each
and total absorbed dose up to 75 Gy.
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Following radiation treatment, animals were removed from the
ﬁxation platform and fully recovered from anesthesia. Animals
were then returned to the vivarium and maintained under
standard care and diet with free access to food and water. All
animals were observed daily by vivarium personnel, and weekly
by one of the investigators until scheduled for sacriﬁce or removed
from study due to the development of symptomatic chronic
proctitis (changes in stool quality, mucosal or bloody discharge,
weight loss, abdominal distension).
Preparation of specimens for histological studies
Following sacriﬁce, the anus, rectum, and a portion of the
colon-rectum were exposed, measured in situ, then marked with
permanent ink to indicate levels corresponding to the anus, and
2.5, 5, and 7 cm along the rectum. The terminal portions of the GI
tract were then removed from the abdominal cavity and pinned to
a Styrofoam ﬂat so as to preserve the physical dimensions
observed in situ. The levels from 2.0 cm to 6.5 cm were cut into
sequential 5 mm blocks for ﬁxation in 4% formaldehyde, and then
embedded in parafﬁn. Sections from each block were cut at a
thickness of 5 microns and stained with hematoxylin–eosin. The
number of crypts on the rectal circumference was counted to
assess the effect of proton irradiation and MnTE-2-PyP5þ treat-
ment on the epithelial population (specimens derived from
animals sacriﬁced 10–23 days post-irradiation). Rectal distension
was assessed by measuring the area bounded by the rectal mucosa
(cut in cross-section).
Statistics
All quantitative measures are reported as means7standard
error; group means were compared using the student t-test.
A Log-Rank test was used to test the hypothesis that the time to
development of chronic radiation proctitis was affected by SOD
mimic administration. In all cases, statistical signiﬁcance was
assumed at po0.05.
Results
Radiation-based rectal injury
Acute phase
In evaluating the evolution of the acute proctitis, it was observed
that the irradiated rats showed a characteristic sequence of radiation
changes beginning with crypt loss and surface ulceration, which with
time would be followed by crypt repopulation and regeneration
(Fig. 2). This latter phase was largely completed by 23 days post-
irradiation with 21.5 Gy. In the ﬁrst phase we observed an initial
shrinkage and collapse of the mucosal cellular architecture. Crypt
mitoses decreased and stopped; cell outlines became indistinct; and
then the cell was lost.
The deterioration was progressive, leading to crypt loss and
surface denudation, which varied from moderate to severe in the
irradiated animals (Fig. 3).
Radioprotective effects of MnTE-2-PyP5þ
Acute phase
Animals treated with the MnTE-2-PyP5þ administered (5 mg/
kg, s.c.) either 1 h before or after irradiation, had a signiﬁcantly
greater number of crypts than untreated animals 10 days after
irradiating the rectum with 21.5 Gy (Fig. 4). The smallest loss of
crypts occurred in the pre-treated animals (61710% reduction in
crypt density as compared to animals receiving no radiation).
Animals which were given MnTE-2-PyP5þ as a post-treatment
were observed to have a 7377% reduction in crypt density, while
those receiving no treatment 9272%. MnTE-2-PyP5þ treatment
had no signiﬁcant effect on mucosal crypt density in animals
receiving no radiation.
Fig. 2. The acute temporal effects of radiation therapy upon rectal mucosa. Temporal changes in the rectal mucosa following irradiation with 21.5 Gy from 10 to 16 and 23
days after radiation; Panel A. Control mucosa from an unirradiated rat; Panel B. 10 days post-irradiation. Ulcerated surface of the mucosa with a single surviving crypt on the
opposing surface; Panel C. Repopulating crypts observed 16 days post irradiation; Panel D. Repopulated crypts 23 days following irradiation. The H&E staining was done at
100-fold magniﬁcation. 6 rats per group were studied.
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Chronic phase
Two chronic studies were performed. In the ﬁrst, all animals
(6 per group) were randomized into one of the three treatment
regimens prior to irradiation with 21.5 Gy: Group with no
MnTE-2-PyP5þ treatment; Group with Pre-treatment (MnTE-2-PyP5þ ,
5 mg/kg subcutaneous, administered 1 h prior to irradiation and at
weekly intervals thereafter); and group with Post-treatment (with the
initial dose of MnTE-2-PyP5þ , 5 mg/kg s.c., given 1 h after irradiation).
Animals receiving MnTE-2-PyP5þ 1 h prior to irradiation showed
no untoward signs or symptoms, and remained active throughout
the subsequent 150 days of observation. Animals showed normal
weight gain throughout the post-irradiation interval. Gross and
histological examination revealed no abnormal ﬁndings.
In the group given MnTE-2-PyP5þ 1 h post irradiation, 4 of the
6 animals became moribund prematurely and were removed from
study; 2 out of these 4 had rectal dilation and diarrhea, and 2 more
displayed intensive inﬂammatory inﬁltrates with mucosal ulceration
and denuded mucosal surfaces typical of the histological changes
described by Trott. The two surviving animals continued to receive
MnTE-2-PyP5þ injections for the remaining weeks of observation.
These surviving animals showed normal weight gain. At necropsy on
day 150, diarrhea and a dilated rectum were noted. At biopsy, the
mucosa was intact although the lumen was markedly dilated (Fig. 5).
The mucosa was re-epitheliated and hyperplastic. Similar ﬁndings
were noted in the untreated, irradiated animals.
Rectal dilation in these animals was quantiﬁed at the time of
necropsy. The average areas of the rectal lumen for the untreated
and post-treated irradiated animals were 57.175.1 mm2 and 57.27
4.1 mm2. In both cases, the measured areas were signiﬁcantly greater
than those observed in control (non-irradiated) cohorts (17.47
2.4 mm2) or in pre-treated animals (15.971.5 mm2).
In a second series, we examined the effects of the MnTE-2-
PyP5þ pre-treatment and radiation dose on the time to develop-
ment of clinical signs of chronic proctitis (diarrhea, mucosal or
bloody discharge, weight loss, abdominal distension). As expected,
the time to onset of chronic proctitis was radiation dose depen-
dent, with higher doses associated with earlier onset of clinical
signs. MnTE-2-PyP5þ treatment signiﬁcantly delayed or prevented
the development of chronic proctitis at the lower radiation doses
examined (20, 25, and 30 Gy). The protective effects of treatment
were not observed in animals irradiated with the 35 Gy dose.
These ﬁndings are summarized in Fig. 6.
Fig. 3. The variability of the acute effects of radiation upon rectal mucosa. Acute radiation effects on the rectal mucosa, 10 days following irradiation with 21.5 CGE. The
continuous mucosa observed in normal rectal tissue (Panel A) was markedly disrupted in all the irradiated animals studied. The severity of this effect was variable as
demonstrated in panels B, C and D, representative of moderate, severe and near total loss of the rectal mucosal lining. The magnitude of crypt loss observed at 10 days post
irradiation was reduced by both pre-treatment and post-treatment with systemically administered MnTE-2-PyP5þ as shown in Fig. 4. The H&E staining was done at 40-fold
magniﬁcation. 6 rats per group were studied.
Fig. 4. Acute protective effects of MnTE-2-PyP5þ (MnP) on the radiation-based loss
of crypts. Control group of rats received no radiation and no MnP administration.
MnP group received no radiation, only MnP administration. Rad group received
radiation and no MnP treatment. The surviving number of crypts is presented
facing the basement membrane on the circumference of the rectum in animals
euthanized at 10 days after focal irradiation of a 2.5 cm segment of the rectumwith
single fraction of 21.5 Gy. RadþMnP groups: Pre-treatment dosage: MnTE-2-Py5þ
(5 mg/kg s.c.) administered 1 h before irradiation and 7 days post-irradiation. Post-
treatment dosage: MnTE-2-PyP5þ (5 mg/kg s.c.) administered 1 h and 7 days post-
irradiation. nSigniﬁcantly higher than other groups (po0.05); † Signiﬁcantly lower
than other groups (po0.05). 6 rats per group were studied.
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None of the animals developed hydronephrosis during the 225
days following irradiation, the termination point for the second
chronic series. Histological examination performed after necropsy
showed characteristic signs of chronic proctitis, including mucosal
atrophy, inﬂammation, submucosal ﬁbrosis and vasculopathy.
Discussion
Following a single dose fraction of 21.5 Gy, an acute proctitis
was produced. The response was ameliorated by MnTE-2-PyP5þ
administration. The number of crypts in the group receiving
MnTE-2-PyP5þ 1 h prior to irradiation was larger by a factor of
ﬁve than the group given proton irradiation and no MnTE-2-
PyP5þ . All irradiated groups survived the acute proctitis period.
This indicates that the surviving cell fractions were able to replace
the cells lost. The time elapsed between the acute proctitis and
onset of diarrhea and rectal dilation in the present study over-
lapped the proctitis described by others. Since we did not wish to
duplicate previous efforts to deﬁne the ED50 for development of
chronic proctitis at 150 days, 21.5 Gy was used as the target dose
and 150 days as the time lapse to euthanize the survivors based on
ﬁndings reported by Hubmann [12]. A noteworthy observation in
the present study was the uniform gross changes of dilation seen
in untreated and post-treated, irradiated animals under these
conditions. Tamou and Trott also observed stretching of the
rectum and a progressive distensibility up to the 29th week
post-irradiation [48]. These observations do not preclude that
the other late effects were evolving and so reﬂect a period of
chronic proctitis. We consider our own observations consistent
with Trott's deﬁnitions of chronic proctitis.
The uniform dilation of the rectum at 150 days seen in this
work was consistent with earlier ﬁndings and conclusions of van
den Aadweg, suggesting that dilation may precede inﬂammatory
changes, mucosal atrophy, and scarring [47]. Moribund rats
removed from the present study for humane reasons presented
with the rectal changes noted by Trott, and all untreated and post-
treated rats surviving to 150 days presented with rectal dilation
and diarrhea. This sequence implies continuity between our own
and previous histologic studies and suggests that if the observa-
tions had continued longer than 5 months the mucosal atrophy,
inﬂammation, and scarring phases described by Trott might
have appeared. This was conﬁrmed in our second chronic series.
Another difference existing between the present and earlier
studies results from an expectation that a point of stricture exists
between the dilated rectum and the irradiated rectum. We found
no evidence for the formation of a ﬁbrotic stricture in any of the
animals studied. A suggested explanation was that a pseudo
stricture point resulted from muscular atony produced by irradia-
tion. These different histological results reﬂect, presumably, the
difference in the selected protocol conditions. We utilized a 1.5-
cm-wide proton beam of ﬁxed length (2.5 cm) to irradiate male
Sprague-Dawley rats. Trott's group used a 1.0-cm wide beam of
lengths that varied up to 5 cm long, a spread of single dose
fractions using 300 kV X rays and female Wistar rats. It is well to
recall that there are reported differences in biological response
between X-ray and protons [49].
Breiter and Trott showed that following a fractionated time–
dose schedule of 6, 7, or 8 Gy delivered at 10-day intervals over a
period of 170 days (18 dose fractions in 170 days), an acute
proctitis did not occur. Late proctitis did occur over the ensuing
160 days [17]. This suggests that the casual elements were delayed
but connected (masked). Similarly, animals fed a low-ﬁber diet did
not develop an acute proctitis, but when the original diet was
restarted a chronic proctitis with intestinal obstruction appeared
after a period of a week [50]. This observation also documents the
importance of the fecal pellets as a necessary causal element and
indicates an additional latent period.
Another example suggesting a variable latent period was that
the irradiation of 18 rats with a 1010 mm ﬁeld did not produce
signs of an acute proctitis or, later, a chronic proctitis. However,
when a 35 mm10 ﬁeld was superimposed over the smaller
Fig. 5. The chronic effects of radiation and the efﬁcacy of MnTE-2-PyP5þ in suppressing rectal dilation. Photomicrographs of rectal cross-sections were taken at 150 days
post-irradiation, demonstrating rectal dilation and the effects of MnTE-2-PyP5þ treatment. Panel A relates to unirradiated control group. Typical specimen obtained from
animals receiving MnTE-2-PyP5þ 1 h prior to receiving 21.5 Gy protons (Panel B) and MnTE-2-PyP5þ 1 h after receiving 21.5 Gy protons (Panel C). Panel D: Specimen taken
from animal receiving 21.5 Gy protons without MnTE-2-PyP5þ treatment. Note the hyperplastic mucosa in Panels C and D which was a typical ﬁnding in both treatment
groups. The H&E staining is shown at 25-fold magniﬁcation. 6 rats per group were studied.
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irradiation area, a chronic proctitis appeared. Eleven ulcers extended
throughout the boost ﬁeld, while 7 were limited to the original small
ﬁeld, with a latency of 350 days post irradiation. Involvement of the
larger ﬁeld had an average latency of 300 days following the boost
[9]. The chronic ulceration and histological changes in these rats
were identical to the changes produced by single-dose fractions
with a shorter latency of 115 days. Black et al. irradiated the rectum
with a single dose fraction to deliver a total dose of 20–50 Gy, and
60–100 Gy using ﬁve or ten fractions. Mucosal changes consisted of
ulceration, colitis, cystica profunda, atypical epithelial regeneration,
ﬁbrosis, or vascular sclerosis in non-capillary vessels. All of these
abnormalities were observed in the present study at the higher dose
range examined. Severe lesions included chronic deep ulcers,
ﬁstulae, and high-grade strictures. Ulceration did not occur as an
isolated lesion [14]. None of these lesions were detected in the
present series.
Clinical relevance of rat study
In clinical settings, normal tissue complication probability
(NTCP), for example the risk of developing proctitis following
pelvic RT, determines dose delivered to the treatment target – the
tumor. In the present study, a dose range was studied that would
encompass the NTCP encountered clinically. In that sense, the
doses are clinically relevant. However, the radiosensitivity of the
GI epithelium depends in part on the volume of tissue irradiated.
Indeed, had the 20–30 Gy dose been delivered to the whole body, or
even the entire gut, none of those animals would survive. Nor would
a single fraction, 20–30 Gy dose of proton or X-radiation be used in
radiation treatment (RT) outside of radiosurgical applications (in
which a toxic dose of radiation is intentionally delivered to a target).
As a general rule, the smaller the volume of the tissue, the less
radiosensitive the tissue is. Rodent models of RT-related radiotoxicity
require greater total dose than would be used clinically to produce a
toxicity endpoint of interest such as GI epithelial damage. However,
in rodent radiotoxicity studies the relatively small volumes of
irradiated tissue involved necessitates, increasing the effective dose
beyond that which would be used clinically to produce the desired
endpoint for study, i.e. proctitis. This is a signiﬁcant source of
uncertainty in extrapolating from rodent models to humans. Thus,
the question is whether the mechanism by which the single fraction
radiation dose delivered to rats damages the GI epithelial and
triggers symptoms of proctitis is the same as the mechanism which
occurs with fractionated treatment doses used clinically. This issue
would have to be resolved in follow up studies in which various
degrees of hypofractionation are studied.
Therapeutic vs. cytotoxic effects of Mn porphyrin-based SOD mimics
The radiation dose-dependent data obtained in the range of
20–35 Gy prove that the magnitude of oxidative stress has large
impact on the type and magnitude of the outcome. MnTE-2-PyP5þ
was radioprotective up to 30 Gy, but not at 35 Gy (Fig. 7). More-
over it increased the number of rats with proctitis, thus enhancing
radiation damage. Until recently we would not have understand
such opposing effects. The master transcription factor, NF-κB plays
a major role in the actions of Mn porphyrins. Our data collected
thus far taught us that the action of Mn porphyrins upon inhibition
of this antiapoptotic prosurvival transcription factor occurs via
oxidation of cysteines of NF-κB subunits p50 and p65 in the
presence of GSH and H2O2 which prevents its DNA binding and
in turn its transcriptional activity [21,26]. Subsequent comprehen-
sive aqueous chemistry and biology studies [21,25,51] support a
major role of H2O2 in the actions of Mn porphyrins. At low levels of
H2O2, the limited inhibition of NF-κB DNA binding would suppress
excessive inﬂammation, while at high levels of H2O2 the major
Fig. 7. Schematic presentation of the dependence of shift of anti- (therapeutic)
to pro-oxidative (cytotoxic) outcome of Mn porphyrin-based therapy upon the
magnitude of oxidative stress as a consequence of the magnitude of radiation.
The data relate to 100 and 220 days after radiation. Blue bars indicate results from
MnP-treated rats, while red bars relate to radiation-only treated rats. The fraction
of rats which developed radiation proctitis is given on Y-axis. In the range of
20–30 Gy MnTE-2-PyP5þ is radioprotective, reducing the fraction of rats with
proctitis. At radiation doses above 30 Gy, Mn porphyrin ampliﬁed the cytotoxic
effects of radiation. (For interpretation of the references to color in this ﬁgure
legend, the reader is referred to the web version of this article.)
Fig. 6. The fraction of rats developing radiation proctitis is dependent upon the dose
of radiation and MnTE-2-PyP5þ treatment. Kaplan–Meier plots showing the effects of
radiation dose and MnTE-2-PyP5þ treatment on the time to onset of symptoms of
chronic proctitis in irradiated rats. For each dose, the fraction of animals entered into
study which exhibited symptoms of chronic proctitis are shown for days 60 through
225. MnTE-2-PyP5þ treatment (weekly subcutaneous administration of 5 mg/kg
beginning 1 h before irradiation) delayed or prevented the development of symptoms
of chronic proctitis, an effect which dependent on the radiation dose delivered. No
beneﬁcial effects of MnTE-2-PyP5þ treatment were observed at the highest radiation
dose tested. 6 rats per group were studied.
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suppression of NF-κB would result in apoptosis and eventually cell
death. Such shift in the nature of effects produced by MnTE-2-
PyP5þ is schematically presented in Figs. 7 and 8. At day 100 after
35 Gy radiation, no chronic proctitis was found with MnTE-2-
PyP5þ-non-treated rats, but 40% rats have proctitis in MnTE-2-
PyP5þ-treated group. Similar cytotoxic effect of MnP was observed
at day 220 after 35 Gy radiation.
We have recently demonstrated a similar scenario in a diabetes
study. The methyl analog, MnTM-2-PyP5þ , reduced kidney damage
in a sreptozotocin rat model of diabetes when its administration
started at the onset of diabetes (24 h after STZ injection) [26]. Yet,
when Mn porphyrin therapy started 8 days after the onset of
diabetes, the cytotoxic effects, i.e. the enhancement of kidney damage
has been observed [26]. We have depicted such opposite effects of
MnP in diabetes and rectum radioprotection study in Fig. 8.
Such differential effects – cytoprotective if the disease has not
advanced beyond certain threshold and cytotoxic if oxidative
stress is ragging – is presently explored with cancer radiation
therapy to our advantage in killing tumor (tissue of excessive
oxidative stress), but healing the normal tissue.
Finally, in several other studies, when Mn porphyrin has been
administered with excessive amounts of ascorbate (H2O2 produ-
cing system), only the cytotoxic action has been observed [52–56].
Such system is in development for tumor treatment with us and
others. Further studies are in progress to clarify the role of Mn
porphyrins and reductants in healing the normal tissue, yet killing
the cancer cell.
Conclusions
Rectal proctitis is a severe clinical problem that occurs at acute
and chronical level as a consequence of abdominal and pelvic
radiations. MnTE-2-PyP5þ proved efﬁcacious in protecting lower
part of colon from radiation. All rats survived the acute proctitis
following irradiation of the 2.5 cm rectal segment with up to
35 Gy. This indicates that a sufﬁcient fraction of epithelial cells
survived and were capable of re-populating the mucosa. The
administration of MnTE-2-PyP5þ either immediately before or
after irradiation protects against radiation induced crypt loss.
When MnTE-2-PyP5þ was administered 1 h before proton irradia-
tion (21.5 Gy), it protected against the development of delayed
rectal dilation, mucosal changes, or diarrhea. However none of
those effects were observed if MnTE-2-PyP5þ was administered
1 h after radiation. The pretreatment with MnTE-2-PyP5þ , with
weekly MnP administration and radiation dose of up to 30 Gy
after, delayed the development of chronic proctitis. Signiﬁcantly
protective effects are produced with 21.5 Gy, which is far away
from the dose (35 Gy) where MnP enhanced the radiation
toxicity.
The nature and the magnitude of the effects of MnTE-2-PyP5þ-
based radiation therapy largely depend upon the magnitude of the
oxidative stress produced by radiation: at lower radiation doses
MnTE-2-PyP5þ is radioprotective, but enhances radiation damage
at higher radiation doses. Under latter conditions it presumably
(based on the correlation of the results of this and earlier studies)
employs excessive oxidative stress, produced by high radiation
dose, more speciﬁcally the H2O2, to catalyze the vast oxidation of
pro-survival proteins/transcription factors and simple molecules
essential for supplying the reducing equivalent for metabolic
processes.
MnTE-2-PyP5þ and the related low molecular-weight cationic
N-substituted pyridyl- and N,N’-disubstituted imidazolylpor-
phyrin-based SOD mimics, who exhibit the ability to normalize
the cellular redox environment and promote survival, warrant
further investigation as adjunctive treatment along with radio-
therapy of tumors located in the abdominal and pelvic regions.
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